Elekta v. ZAP Surgical Systems: Radiosurgery Patent Battle Ends in Settlement
Elekta Ltd. and Elekta Inc. sued ZAP Surgical Systems over its ZAP-X Gyroscopic Radiosurgery Platform, asserting US patent 7,295,648. After more than five years of litigation in the Northern District of California, the parties reached a confidential settlement and the case was dismissed with prejudice — each side bearing its own legal costs.
Five-year radiosurgery IP fight ends in confidential settlement
In April 2019, Elekta Limited and its US subsidiary Elekta Inc. — a leading developer of radiation therapy and radiosurgery systems — filed a patent infringement action against ZAP Surgical Systems, Inc. in the United States District Court for the Northern District of California (Case No. 4:19-cv-02269). The suit centred on US Patent No. 7,295,648, asserting that ZAP Surgical’s ZAP-X Gyroscopic Radiosurgery Platform infringed Elekta’s patented technology for delivering highly focused radiation beams in cranial radiosurgery applications.
The litigation concluded on 12 June 2024, when the parties filed a joint stipulation confirming they had entered into a confidential settlement agreement. The court dismissed the case with prejudice — meaning neither party may refile claims arising from this dispute — and ordered that each side bear its own attorneys’ fees and costs. A dismissal with prejudice on settled terms is the standard mechanism by which parties extinguish all asserted claims and defences without a judicial merits ruling.
At 1,874 days, the case ran significantly longer than the median patent case lifespan in N.D. Cal., suggesting protracted claim construction, discovery, or inter partes proceedings before resolution. The mutual cost-bearing provision is consistent with a negotiated resolution rather than a capitulation by either side. The financial and licensing terms of the settlement are not disclosed in the public record, leaving open questions about cross-licensing, design-around obligations, or market-sharing arrangements between the two competitors.
Filing to Dismissed with Prejudice in 1874 days
1,874 days — well above the median ~730-day patent case lifespan in N.D. Cal.
Settled with prejudice: what the joint stipulation means for both parties
Dismissal with prejudice ends all claims permanently
A dismissal with prejudice under Federal Rule of Civil Procedure 41(a) is a final, on-the-merits termination of all claims. Neither Elekta nor ZAP Surgical may refile any of the asserted claims or defences from this action in any future proceeding. The stipulated dismissal was entered jointly by both parties’ counsel and confirmed by the court, giving it full preclusive effect.
Permanent bar on refilingElekta secures permanent closure — on undisclosed terms
Elekta initiated the action and agreed to a with-prejudice dismissal, which typically signals that the settlement delivered sufficient commercial value to justify extinguishing the suit. The confidential settlement terms may include a license, royalty, design-around commitment, or market arrangement. Elekta retains US7295648B2 as an enforceable asset and remains free to assert it against other parties.
Patent remains enforceableZAP Surgical resolves infringement cloud over ZAP-X platform
ZAP Surgical exits the litigation without a judicial finding of infringement. The with-prejudice dismissal removes the overhang of this specific action from the ZAP-X product line. However, the confidential nature of the settlement means the precise terms — including any ongoing obligations regarding US7295648B2 — are unknown from the public record. The mutual cost-bearing clause suggests neither side conceded a decisive advantage.
No infringement finding on recordRadiosurgery IP landscape remains active after settlement
This settlement does not resolve the underlying validity or scope of US7295648B2 — meaning third-party radiosurgery developers face continued uncertainty when designing competing platforms. The five-year duration suggests the patent’s claims were vigorously contested, which may indicate non-trivial claim scope questions. Competitors in the stereotactic radiosurgery and LINAC-based treatment delivery market should monitor any licensing activity by Elekta post-settlement.
Scope of US7295648B2 unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Elekta Co. | Company | Radiation therapy & radiosurgery systems developer — holder of US7295648B2Search in Eureka ↗ |
| Co-Plaintiff | Elekta, Inc. | Company | Search in Eureka ↗ |
| Defendant | ZAP Surgical Systems, Inc. | Company | Medical device company; developer of the ZAP-X Gyroscopic Radiosurgery PlatformSearch in Eureka ↗ |
| Plaintiff counsel | Ronald Scott Lemieux | Attorney | Counsel for Elekta Co.Search in Eureka ↗ |
| Plaintiff counsel | Tamara E. Fraizer | Attorney | Counsel for Elekta Co.Search in Eureka ↗ |
| Plaintiff law firm | Squire Patton Boggs LLP | Law Firm | Representing Elekta Co.Search in Eureka ↗ |
| Defendant counsel | A. James Isbester | Attorney | Counsel for ZAP Surgical Systems, Inc.Search in Eureka ↗ |
| Defendant counsel | April Elizabeth Isaacson | Attorney | Counsel for ZAP Surgical Systems, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew Joseph Meyer | Attorney | Counsel for ZAP Surgical Systems, Inc.Search in Eureka ↗ |
| Defendant law firm | Kilpatrick Townsend & Stockton, LLP | Law Firm | Representing ZAP Surgical Systems, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal language is precise: all claims and defences are dismissed with prejudice, each party bears its own costs, and the court is asked to close the docket. This phrasing confirms a bilateral, negotiated resolution — not a unilateral capitulation. The ‘with prejudice’ designation is legally significant: it bars any future re-assertion of the same claims, providing ZAP Surgical with finality. However, no court has construed the claims of US7295648B2 or ruled on validity, leaving the patent’s enforceability scope unaddressed for third parties.
US7295648B2 — Radiation beam delivery system for radiosurgery
US Patent No. 7,295,648 (application no. US10/971,298) covers technology in the domain of radiation beam delivery for radiosurgery — the precise, non-invasive treatment of intracranial targets using focused ionising radiation. The patent’s application lineage places its priority in the early-to-mid 2000s, a period of rapid development in image-guided and robotic radiosurgery systems. The asserted patent covers technical methods or apparatus central to how a radiosurgery platform acquires, aligns, and delivers treatment beams to a target with sub-millimetre accuracy.
For the radiosurgery sector, US7295648B2 is strategically significant: Elekta is a dominant incumbent in the radiation oncology market, and this patent’s assertion against ZAP Surgical’s flagship product suggests it covers architecture-level innovations rather than peripheral features. Any competitor developing a gyroscopic, robotic, or isocentric radiosurgery delivery system should regard this patent as a potential blocking position. The absence of a final validity or claim construction ruling means the patent’s full commercial scope remains untested in court, preserving Elekta’s optionality for future enforcement.
Should you run an FTO against US7295648B2?
Any R&D team or product company developing a radiosurgery platform — particularly gyroscopic, isocentric, or robotically guided systems — should treat US7295648B2 as a priority FTO target. The patent was asserted against ZAP Surgical’s entire commercial platform after five years of litigation, suggesting Elekta views it as covering core delivery architecture. No court has construed the claims, meaning scope uncertainty is high. Medical device OEMs, beam delivery system integrators, and treatment planning software vendors building into the cranial radiosurgery workflow should evaluate their exposure before commercial launch or fundraising.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claims of US7295648B2 in minutes, flagging overlap risk and surfacing prior art that may support design-around strategies or invalidity arguments. Eureka also monitors the patent’s assignment history, maintenance status, and any continuation filings — giving your IP team real-time visibility into Elekta’s portfolio posture and any new enforcement signals that emerge after this settlement.
Run a freedom-to-operate analysis on US7295648B2 to assess your product’s exposure
Run FTO in Eureka →Similar radiosurgery and radiation therapy patent cases in N.D. Cal.
Cases involving radiation delivery system patents in the Northern District of California, where Elekta v. ZAP Surgical was litigated over the ZAP-X platform.
What this case signals for the radiosurgery IP landscape
A five-year patent battle between the two leading radiosurgery platform developers carries lessons well beyond the parties themselves.
Long litigation duration signals hard-fought claim scope, not a quick surrender
At 1,874 days, this case far exceeded the N.D. Cal. median. That duration typically signals contested Markman hearings, IPR proceedings, or complex damages discovery. Competitors entering the radiosurgery market should treat US7295648B2 as a patent with contested but potentially broad claims — not one easily designed around.
Mutual cost-bearing is the tell: neither party capitulated
When a plaintiff agrees to each side bearing its own costs, it generally indicates the settlement was commercially negotiated rather than a defendant surrender. ZAP Surgical avoided any fee-shifting, suggesting it maintained credible invalidity or non-infringement arguments throughout — worth noting for any future licensee or challenger of this patent.
Elekta v ZAP — key questions answered
The case settled and was dismissed with prejudice by joint stipulation on 12 June 2024. The parties entered a confidential settlement agreement covering all claims and defences. Each party agreed to bear its own attorneys’ fees and costs. No court ruled on infringement, validity, or claim construction.
Elekta asserted US Patent No. 7,295,648 (B2), application number US10/971,298. The patent covers radiation beam delivery technology relevant to radiosurgery platforms. It was asserted against ZAP Surgical’s ZAP-X Gyroscopic Radiosurgery Platform, ZAP Surgical’s flagship commercial product.
A with-prejudice dismissal means Elekta cannot refile these specific claims against ZAP Surgical in any future proceeding. It removes the immediate litigation cloud over the ZAP-X product. However, it does not constitute a finding of non-infringement or invalidity of US7295648B2, and the patent remains enforceable against other parties.
The case lasted 1,874 days — approximately five years and two months — significantly longer than the median patent case in N.D. Cal. This duration typically suggests contested claim construction proceedings, discovery disputes, or parallel IPR challenges. It is consistent with a vigorously contested dispute in which neither party achieved an early dispositive ruling.
Not directly, but it has important implications. US7295648B2 remains in force and was never held invalid or construed by the court. Third-party radiosurgery developers cannot rely on this settlement as evidence of limited claim scope or weakness. Any company with a competing product in the gyroscopic or isocentric radiosurgery space should conduct an independent FTO analysis against this patent.
PatSnap Eureka searches patents and litigation data to answer instantly.